Sigachi Laboratories Limited Unlisted Share
₹52▲0.00%(0.00)
About the company
Sigachi Laboratories Limited is an Indian pharmaceutical company engaged in the manufacturing and supply of bulk drugs, drug intermediates, and pharmaceutical products. The company operates from its registered office and manufacturing facility in Sangareddy District, Telangana, and has established its presence in the pharmaceutical sector by focusing on quality manufacturing, regulatory compliance, and operational efficiency.
The company's core business revolves around producing pharmaceutical ingredients that serve as essential building blocks in the manufacturing of medicines. In addition to its pharmaceutical operations, Sigachi Laboratories also generates income from interest on loans, inter-corporate deposits (ICDs), and fixed deposits, contributing to its overall financial performance.
Fundamentals
Valuation
| Metric | Value |
|---|---|
| 52 week high | ₹52 |
| 52 week low | ₹52 |
| P/B ratio | 0.89 |
| Debt to equity | 0 |
| ROE (%) | 3.03% |
| Book value | ₹58.39 |
| Face value | ₹10 |
52 week high
52 week low
P/B ratio
ROE (%)
| Metric | Value |
|---|---|
| 52 week high | ₹52 |
| 52 week low | ₹52 |
| P/B ratio | 0.89 |
| ROE (%) | 3.03% |
Registry
| Metric | Value |
|---|---|
| PAN number | AACCS8220M |
| ISIN number | INE368H01018 |
Figures in lk ·
Financials
| P&L Statement | 2025Latest | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 312 | 374 | 195 | 260 | 348 | 66 | 169.54 | 176.24 |
| EBITDA | 109 | 242 | 142 | 211 | 293 | 25 | 113.89 | 113.64 |
| OPM | 34.94 | 64.71 | 72.82 | 81.15 | 84.2 | 37.88 | 67.18 | 64.48 |
| PBT | 152 | 281 | 173 | 238 | 314 | 116 | 127.39 | 133.89 |
| PAT | 119 | 197 | 131 | 200 | 276 | 70 | 104.51 | 111.1 |
| EPS | 1.63 | 2.69 | 1.79 | 2.74 | 3.78 | 0.96 | 1.43 | 1.52 |
Shareholding Pattern
Promoters
Resident Individual
NRI
Others
| Holder | Percentage |
|---|---|
| Promoters | 36.86% |
| Resident Individual | 40.59% |
| NRI | 20.48% |
| Others | 2.07% |
Leadership
| Name | Role | Experience | |
|---|---|---|---|
| Sri. T. Adinarayana | Chairman | 30+ yrs experience | — |
| Sri. T.R. Sekhar | Executive Director | 25+ yrs experience | — |
| Mr. B. Kumar | CFO | 25+ yrs experience | — |
Frequently asked questions
Common questions on Sigachi Laboratories Limited Unlisted Share—tap a row to read the answer.
Q.1What is Sigachi Laboratories Limited?
Sigachi Laboratories Limited is an Indian pharmaceutical company engaged in the manufacturing of bulk drugs, drug intermediates, and other pharmaceutical products. The company also earns income from interest-bearing investments such as inter-corporate deposits (ICDs), loans, and fixed deposits. With its focus on quality manufacturing and operational efficiency, the company serves the pharmaceutical industry's growing demand for active ingredients and intermediates.
Q.2Can I invest in Sigachi Laboratories Limited unlisted shares?
Yes, if Sigachi Laboratories Limited unlisted shares are available in the private market, eligible investors can purchase them through private share transactions. Since these shares are not traded on major stock exchanges, their availability depends on existing shareholders willing to sell and prevailing market demand.
Q.3How can I buy Sigachi Laboratories Limited unlisted shares?
You can buy Sigachi Laboratories Limited unlisted shares through authorized intermediaries that facilitate private share transactions. Once the price, quantity, and documentation are finalized, the shares are transferred electronically to your Demat account after successful payment and verification.
Q.4How is the price of Sigachi Laboratories Limited unlisted shares determined?
The price of Sigachi Laboratories Limited unlisted shares is generally influenced by several factors, including the company's financial performance, profitability, business outlook, pharmaceutical industry trends, recent private market transactions, investor demand, and overall market sentiment. Since the shares are privately traded, prices are determined through negotiations rather than exchange-based trading.
Q.5Is it legal to buy Sigachi Laboratories Limited unlisted shares in India?
Yes. Buying and selling unlisted shares is legal in India when the transaction complies with applicable laws and regulatory requirements. Investors should ensure that the transfer is completed with proper documentation and that the shares are credited to their Demat account.
Q.6Do I need a Demat account to hold Sigachi Laboratories Limited unlisted shares?
Yes. An active Demat account is generally required to receive and hold Sigachi Laboratories Limited unlisted shares in electronic form. It provides secure ownership records and makes future transfers or sales more convenient.
Unlisted Trending shares
High-demand unlisted opportunities currently available for trade.
MARKET INSIGHTS & UPDATES
Read the latest updates, investment ideas, and market insights designed to help investors better understand unlisted and pre-IPO opportunities.

NSE IPO 2026: Dates, Allotment & Listing Details
The much-awaited NSE IPO is set to make a major market debut in September 2026. As per the announced schedule, the IPO will open on 21 September and close on 23 September 2026, followed by share allotment on 24 September and listing on 28 September 2026. With strong investor interest and NSE’s position as one of India’s leading market institutions, the IPO is expected to attract significant attention. Here’s a quick look at the NSE IPO 2026 timeline and important dates investors should know.

Upcoming IPOs in 2026: NSE, Rentomojo, Manipal & Pranav Guide
Four major 2026 IPOs: NSE, Manipal Payment, Rentomojo, Pranav Constructions. For pre-IPO investors, these mark critical transitions from private to public valuations. Conduct due diligence before investing.

Purple Style Labs: From Unlisted Shares to IPO - A Price Journey Worth Noticing
Purple Style Labs is making headlines as it moves from the unlisted market towards its IPO. With its unlisted shares trading around ₹500–₹525 and an IPO price band of ₹546–₹575, the price journey offers an interesting look at how private-market and IPO valuations can differ.

Muthoot FinCorp Unlisted Shares: Q1FY27 Profit Surges to ₹705 Cr | Fundamentals & IPO
Muthoot FinCorp's Q1FY27 profit surged to ₹705.48 crore as the company moves toward a proposed ₹3,000-crore IPO. Here's a look at its financial performance, valuation metrics, asset quality and key fundamentals.

From Debt to Debt-Free: How API Holdings Used Thyrocare to Reshape Its Balance Sheet
API Holdings has repaid ₹1,050 crore of debt by monetising a 9.90% stake in Thyrocare while retaining 51.02% control. Here's how the move reshapes its balance sheet and what it means going forward.

Pre IPO Shares in India: Price, How to Buy & Complete Guide
Learn what Pre IPO Shares are, how their prices are determined, how to buy them in India, and what investors should check before investing in unlisted companies.
